Monoclonal Antibody Therapy in Treating Patients With Colorectal Cancer
NCT00005616 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12
Last updated 2013-06-19
Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients who have colorectal cancer.
Conditions
Interventions
- PROCEDURE
-
conventional surgery
- PROCEDURE
-
neoadjuvant therapy
- PROCEDURE
-
radionuclide imaging
- RADIATION
-
iodine I 131 monoclonal antibody F19
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
Memorial Sloan Kettering Cancer Center
lead OTHER
Principal Investigators
-
Sydney Welt, MD · Memorial Sloan Kettering Cancer Center
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1999-09-30
- Primary Completion
- 2000-08-31
- Completion
- 2000-08-31
Countries
- United States
Study Locations
More Related Trials
-
Monoclonal Antibody Therapy in Treating Patients With Metastatic Colorectal Cancer
NCT00039273 ·Status: COMPLETED ·Phase: PHASE2
-
Edrecolomab in Treating Patients With Stage II Colon Cancer
NCT00002968 ·Status: COMPLETED ·Phase: PHASE3
-
Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer
NCT00284817 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma
NCT00102024 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Monoclonal Antibody Therapy and Colony- Stimulating Factor in Treating Patients With Metastatic Colorectal Cancer
NCT00002664 ·Status: WITHDRAWN ·Phase: PHASE2
-
Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
NCT00544011 ·Status: UNKNOWN ·Phase: PHASE2
-
Radiolabeled Monoclonal Antibody Therapy, Combination Chemotherapy, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
NCT01205022 ·Status: COMPLETED ·Phase: PHASE1
-
Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer
NCT00006046 ·Status: TERMINATED ·Phase: PHASE1
-
Cetuximab in Treating Patients With Stage IV Colorectal Cancer
NCT00020930 ·Status: COMPLETED ·Phase: PHASE2
-
Vaccine Therapy in Treating Patients With Colorectal Cancer Metastatic to the Liver
NCT00033748 ·Status: COMPLETED ·Phase: PHASE2
-
Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer
NCT03307603 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer
NCT00291486 ·Status: COMPLETED ·Phase: PHASE1
-
Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer
NCT05690035 ·Status: WITHDRAWN ·Phase: PHASE2
-
Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer
NCT00575562 ·Status: COMPLETED ·Phase: PHASE1
-
Phase II Trial of Combination Therapy With S-1, Irinotecan, and Bevacizumab (SIRB) in Patients With Unresectable or Recurrent Colorectal Cancer
NCT00569335 ·Status: COMPLETED ·Phase: PHASE2
-
Study Using CP-751,871 In Patients With Stage IV Colorectal Cancer That Has Not Responded To Previous Anti-Cancer Treatments
NCT00560560 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Tolerability and Pharmacokinetics of Recombinant Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal Cancer
NCT02211443 ·Status: UNKNOWN ·Phase: PHASE1
-
Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
NCT00423696 ·Status: COMPLETED ·Phase: PHASE2
-
Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
NCT00467142 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers
NCT05087992 ·Status: COMPLETED ·Phase: PHASE1
-
Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer
NCT03043313 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
NCT01776307 ·Status: COMPLETED ·Phase: PHASE2
-
Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
NCT04117945 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer
NCT03592641 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer
NCT03356158 ·Status: UNKNOWN ·Phase: PHASE1